Exclusive Coverage of the 2018 American Society of Clinical Oncology Annual Meeting

Highlights from the American Society of Clinical Oncology meeting, which took place on June 1-5, 2018 in Chicago, IL are available in this newsletter published by The American Journal of Managed Care.

Download PDF: Exclusive Coverage of the 2018 American Society of Clinical Oncology Annual Meeting

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Justin Balko, PharmD, PhD | Image Credit: Vanderbilt-Ingram Cancer Center

The Biomarker Gap in Triple-Negative Breast Cancer: Justin Balko, PharmD, PhD

ByElla Hohmann, MS,Justin Balko, PharmD, PhD

July 23rd 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

ByBrooke McCormick

July 22nd 2026

Angie Maynard, PharmD, MS | Image Credit: Lipscomb University

Oncology Workflows Shift as Drug Delivery, Monitoring Change: Angie Maynard, PharmD, MS

ByElla Hohmann, MS,Angie Maynard, PharmD, MS

July 22nd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Exclusive Coverage of the 2018 American Society of Clinical Oncology Annual Meeting

Related Content

The Biomarker Gap in Triple-Negative Breast Cancer: Justin Balko, PharmD, PhD

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

Oncology Workflows Shift as Drug Delivery, Monitoring Change: Angie Maynard, PharmD, MS

Geographical Access to Preferred Pharmacies in Medicare Part D

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

Dermatology Practices Absorb Rising Prior Authorization Costs